John Wagner is an Oncology physician. ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2500 Metrohealth Dr
Cleveland, OH 441091998
Telephone
216-778-7344Provider last certified this registry record 13 Apr 2026.
Clinical trials
- StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Sponsor: Masonic Cancer Center, University of Minnesota
- A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Sponsor: Cellerant Therapeutics
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20251 payment
- Astellas Pharma US IncProgram year20251 payment
- National Marrow Donor ProgramProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
60.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor60.9%Acyclovir100%Part D≥24 patientsMetabolism & gastrointestinal
21.9%Serotonin-3 Receptor Antagonist11.7%Ondansetron Odt100%Part D<11 patientsProton pump inhibitor10.2%Pantoprazole Sodium100%Part D<11 patientsAnti-infectives
17.2%Cytomegalovirus DNA Terminase Complex Inhibitor8.6%Prevymis100%Part D<11 patientsShort-acting sulfonamides8.6%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”